TocilizumabV1, France, Analysis, bibRecord, 000437

Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.

Identifieur interne : 000437 ( France/Analysis ); précédent : 000436; suivant : 000438

Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.

Auteurs : Françoise Lunel-Fabiani [France] ; Charles Masson [France] ; Alexandra Ducancelle [France]

Source :

Joint bone spine [ 1778-7254 ] ; 2014.

RBID : pubmed:24561021

Descripteurs français

KwdFr :
- Activation virale (immunologie), Antiviraux (usage thérapeutique), Biothérapie, Facteur de nécrose tumorale alpha (immunologie), Humains, Hépatite B chronique (), Hépatite B chronique (immunologie), Hépatite B chronique (physiopathologie), Risque, Vaccination, Vaccins anti-hépatite B (usage thérapeutique).
MESH :
- immunologie : Activation virale, Facteur de nécrose tumorale alpha, Hépatite B chronique.
- physiopathologie : Hépatite B chronique.
- usage thérapeutique : Antiviraux, Vaccins anti-hépatite B.
- Biothérapie, Humains, Hépatite B chronique, Risque, Vaccination.

English descriptors

KwdEn :
- Antiviral Agents (therapeutic use), Biological Therapy, Hepatitis B Vaccines (therapeutic use), Hepatitis B, Chronic (immunology), Hepatitis B, Chronic (physiopathology), Hepatitis B, Chronic (prevention & control), Hepatitis B, Chronic (therapy), Humans, Risk, Tumor Necrosis Factor-alpha (immunology), Vaccination, Virus Activation (immunology).
MESH :
- chemical , immunology : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antiviral Agents, Hepatitis B Vaccines.
- immunology : Hepatitis B, Chronic, Virus Activation.
- physiopathology : Hepatitis B, Chronic.
- prevention & control : Hepatitis B, Chronic.
- therapy : Hepatitis B, Chronic.
- Biological Therapy, Humans, Risk, Vaccination.

Abstract

Hepatitis B virus (HBV) reactivation can occur in chronic carriers of the HBV surface antigen (HBsAg) and constitutes a well-known complication of immunosuppressive therapy. HBV reactivation has also been reported after contact with the HBV. The increasing use of biological agents (TNFα antagonists, rituximab, abatacept, and tocilizumab) to treat systemic diseases has resulted in numerous publications about the risk of HBV reactivation. The relevant scientific societies have issued recommendations designed to prevent HBV reactivation. The main measures consist of screening for markers indicating chronic HBV infection (HBsAg) or HBV infection in the distant past (antibodies to the HBV core antigen) before initiating biological therapies, vaccinating marker-negative patients, and considering close follow-up or antiviral treatment before immunosuppressive treatment initiation or in the event of HBV reactivation. Here, we discuss the pathophysiological mechanisms underlying HBV reactivation during biological treatments, most notably in patients with occult HBV infection or markers for remote HBV infection, whose hepatocyte nuclei may contain a resistance form of HBV DNA known as covalently closed circular DNA (cccDNA). Assessment of the risk of reactivation relies on the HBV status, drugs used, and data from the literature. Finally, we discuss the various recommendations and modalities for HBV vaccination, preemptive treatment, and patient management, according to the level of risk and to the circumstances in which reactivation occurs.

DOI: 10.1016/j.jbspin.2014.01.015
PubMed: 24561021

Affiliations:

Links to Exploration step

pubmed:24561021

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.</title>
<author><name sortKey="Lunel Fabiani, Francoise" sort="Lunel Fabiani, Francoise" uniqKey="Lunel Fabiani F" first="Françoise" last="Lunel-Fabiani">Françoise Lunel-Fabiani</name>
<affiliation wicri:level="3"><nlm:affiliation>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Angers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Masson, Charles" sort="Masson, Charles" uniqKey="Masson C" first="Charles" last="Masson">Charles Masson</name>
<affiliation wicri:level="3"><nlm:affiliation>Service de rhumatologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France. Electronic address: ChMasson@chu-angers.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de rhumatologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Angers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ducancelle, Alexandra" sort="Ducancelle, Alexandra" uniqKey="Ducancelle A" first="Alexandra" last="Ducancelle">Alexandra Ducancelle</name>
<affiliation wicri:level="3"><nlm:affiliation>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Angers</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24561021</idno>
<idno type="pmid">24561021</idno>
<idno type="doi">10.1016/j.jbspin.2014.01.015</idno>
<idno type="wicri:Area/PubMed/Corpus">001472</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001472</idno>
<idno type="wicri:Area/PubMed/Curation">001472</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001472</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001273</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001273</idno>
<idno type="wicri:Area/Ncbi/Merge">000A41</idno>
<idno type="wicri:Area/Ncbi/Curation">000A41</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A41</idno>
<idno type="wicri:Area/Main/Merge">002334</idno>
<idno type="wicri:Area/Main/Curation">002333</idno>
<idno type="wicri:Area/Main/Exploration">002333</idno>
<idno type="wicri:Area/France/Extraction">000437</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.</title>
<author><name sortKey="Lunel Fabiani, Francoise" sort="Lunel Fabiani, Francoise" uniqKey="Lunel Fabiani F" first="Françoise" last="Lunel-Fabiani">Françoise Lunel-Fabiani</name>
<affiliation wicri:level="3"><nlm:affiliation>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Angers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Masson, Charles" sort="Masson, Charles" uniqKey="Masson C" first="Charles" last="Masson">Charles Masson</name>
<affiliation wicri:level="3"><nlm:affiliation>Service de rhumatologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France. Electronic address: ChMasson@chu-angers.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de rhumatologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Angers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ducancelle, Alexandra" sort="Ducancelle, Alexandra" uniqKey="Ducancelle A" first="Alexandra" last="Ducancelle">Alexandra Ducancelle</name>
<affiliation wicri:level="3"><nlm:affiliation>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de virologie et laboratoire HIFIH, UPRES EA 3859, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Angers</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Joint bone spine</title>
<idno type="eISSN">1778-7254</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Biological Therapy</term>
<term>Hepatitis B Vaccines (therapeutic use)</term>
<term>Hepatitis B, Chronic (immunology)</term>
<term>Hepatitis B, Chronic (physiopathology)</term>
<term>Hepatitis B, Chronic (prevention & control)</term>
<term>Hepatitis B, Chronic (therapy)</term>
<term>Humans</term>
<term>Risk</term>
<term>Tumor Necrosis Factor-alpha (immunology)</term>
<term>Vaccination</term>
<term>Virus Activation (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Activation virale (immunologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Biothérapie</term>
<term>Facteur de nécrose tumorale alpha (immunologie)</term>
<term>Humains</term>
<term>Hépatite B chronique ()</term>
<term>Hépatite B chronique (immunologie)</term>
<term>Hépatite B chronique (physiopathologie)</term>
<term>Risque</term>
<term>Vaccination</term>
<term>Vaccins anti-hépatite B (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Hepatitis B Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Activation virale</term>
<term>Facteur de nécrose tumorale alpha</term>
<term>Hépatite B chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepatitis B, Chronic</term>
<term>Virus Activation</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hépatite B chronique</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hepatitis B, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Vaccins anti-hépatite B</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Biological Therapy</term>
<term>Humans</term>
<term>Risk</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Biothérapie</term>
<term>Humains</term>
<term>Hépatite B chronique</term>
<term>Risque</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hepatitis B virus (HBV) reactivation can occur in chronic carriers of the HBV surface antigen (HBsAg) and constitutes a well-known complication of immunosuppressive therapy. HBV reactivation has also been reported after contact with the HBV. The increasing use of biological agents (TNFα antagonists, rituximab, abatacept, and tocilizumab) to treat systemic diseases has resulted in numerous publications about the risk of HBV reactivation. The relevant scientific societies have issued recommendations designed to prevent HBV reactivation. The main measures consist of screening for markers indicating chronic HBV infection (HBsAg) or HBV infection in the distant past (antibodies to the HBV core antigen) before initiating biological therapies, vaccinating marker-negative patients, and considering close follow-up or antiviral treatment before immunosuppressive treatment initiation or in the event of HBV reactivation. Here, we discuss the pathophysiological mechanisms underlying HBV reactivation during biological treatments, most notably in patients with occult HBV infection or markers for remote HBV infection, whose hepatocyte nuclei may contain a resistance form of HBV DNA known as covalently closed circular DNA (cccDNA). Assessment of the risk of reactivation relies on the HBV status, drugs used, and data from the literature. Finally, we discuss the various recommendations and modalities for HBV vaccination, preemptive treatment, and patient management, according to the level of risk and to the circumstances in which reactivation occurs. </div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Pays de la Loire</li>
</region>
<settlement><li>Angers</li>
</settlement>
</list>
<tree><country name="France"><region name="Pays de la Loire"><name sortKey="Lunel Fabiani, Francoise" sort="Lunel Fabiani, Francoise" uniqKey="Lunel Fabiani F" first="Françoise" last="Lunel-Fabiani">Françoise Lunel-Fabiani</name>
</region>
<name sortKey="Ducancelle, Alexandra" sort="Ducancelle, Alexandra" uniqKey="Ducancelle A" first="Alexandra" last="Ducancelle">Alexandra Ducancelle</name>
<name sortKey="Masson, Charles" sort="Masson, Charles" uniqKey="Masson C" first="Charles" last="Masson">Charles Masson</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000437 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000437 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:24561021
   |texte=   Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:24561021" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.

Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.